1-5 of 5
Yusri A. Elsayed
Close
Sort by
Journal Articles

Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst, Vineet Pande, Ann Marien, Dries Goffin, Daniela V. Wenge, Hong Yue, Jevon A. Cutler, Cyrus Jin, Florian Perner, Shanna M. Hogeling, Paul L Shaffer, Frank Jacobs, Petra Vinken, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Balpreet Bhogal, Karin Verstraeten, Sara El Ashkar, Jennifer A. Perry, Prathiba Jayaguru, Laura Barreyro, Anna Kuchnio, Nicolas Darville, Daniel Krosky, Gregor Urbanietz, Bie Verbist, James P Edwards, Glenn S. Cowley, Robert Kirkpatrick, Ruth Steele, Lucille Ferrante, Christina Guttke, Nikki Daskalakis, E. Christine Pietsch, David Matthew Wilson, Ricardo M Attar, Yusri A Elsayed, Eric S Fischer, Jan Jacob Schuringa, Scott A. Armstrong, Kathryn Packman, Ulrike Philippar
Journal: Blood
Blood blood.2023022480.
https://doi.org/10.1182/blood.2023022480
Published: 2024
Includes: Supplemental data
Journal Articles

Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Anna Kuchnio, Danlin Yang, Nele Vloemans, Cassandra Lowenstein, Ivo Cornelissen, Ricardo Amorim, Chao Han, Siddharth Sukumaran, Lut Janssen, Toon Suls, Mariette Bekkers, Elena Lasorsa, Lorena Fontana, Nicole Medeiros, Bingyuan Wu, Jun Chen, Michael Feldkamp, Sheng-Jiun Wu, Habtom Habte, John Krayer, Cam Holland, M. Phillip Deyoung, Yusri A Elsayed, Ulrike Philippar
Journal: Blood
Blood (2022) 140 (Supplement 1): 3105–3106.
https://doi.org/10.1182/blood-2022-168739
Published: 2022
Journal Articles

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Suzette Girgis, PhD BPharm, MS, Shun Xin Wang Lin, PhD, Kodandaram Pillarisetti, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Shoba Shetty, PhD, Tara Stephenson, PhD, Brandi W. Hilder, PhD, Brett Hanna, Jennifer Smit, Homer Adams III, PhD, Yu-Nien (Tom) Sun, PhD, Jeffrey R. Infante, MD, Yusri A Elsayed, MD PhD, Amarnath Sharma, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-140565
Published: 2020
Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Bertrand Coiffier, MD, Weimin Li, Erin D Henitz, BS, J. D. Karkera, PhD, Reyna Favis, PhD, Dana Gaffney, MS, Alice Shapiro, MS, Panteli Theocharous, BSc (hons), MSc, PhD, Yusri A Elsayed, MD, PhD, Helgi van de Velde, MD, PhD, Evgenii A Osmanov, MD, PhD, Xiaonan Hong, MD, Adriana Scheliga, MD, Fritz C. Offner, MD, PhD, Simon Rule, Adriana C Teixeira, MD, Jan Walewski, MD, PhD, Sven de Vos, MD, PhD, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Pier Luigi Zinzani, MD, PhD, Andrew Z Cakana, MD, FRCPath, Dixie-Lee Esseltine, MD, FRCPC, George Mulligan, PhD, Deborah S Ricci, PhD
Journal: Blood
Blood (2011) 118 (21): 265.
https://doi.org/10.1182/blood.V118.21.265.265
Published: 2011
Journal Articles

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Clinical Trials & Observations
Donna E. Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean-Paul Fermand, Robert A. Vescio, Xiangyang Liu, Yusri A. Elsayed, Andrew Cakana, Raymond L. Comenzo, for the VELCADE CAN2007 Study Group
Journal: Blood
Blood (2009) 114 (8): 1489–1497.
https://doi.org/10.1182/blood-2009-02-203398
Published: 2009
Includes: Supplemental data